1. Search Result
Search Result
Results for "

Fatty acid amide hydrolase

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

2

Fluorescent Dye

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110138

    Others Others
    PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .
    PDP-EA
  • HY-N7062

    Takeda-25

    FAAH Neurological Disease
    JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .
    JNJ-1661010
  • HY-103462

    FAAH Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-14380
    PF-3845
    1 Publications Verification

    FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
    PF-3845
  • HY-W751418

    (Z)-2-tetracos-15-enamidoethanesulfonic acid

    FAAH Neurological Disease
    N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .
    N-Nervonoyl taurine
  • HY-152251

    Cannabinoid Receptor FAAH Inflammation/Immunology
    CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .
    CB2R/FAAH modulator-1
  • HY-U00240

    FAAH Autophagy Neurological Disease
    SA72 is a highly selective fatty acid amide hydrolase (FAAH) inhibitor.
    SA72
  • HY-120961

    N-Ethyloleamide

    FAAH Metabolic Disease
    Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .
    Oleoyl ethyl amide
  • HY-18080

    FAAH Autophagy Metabolic Disease
    SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate .
    SA 47
  • HY-W479534

    DemNA

    Biochemical Assay Reagents Others
    Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).
    Decanoyl m-Nitroaniline
  • HY-10867

    FAAH Metabolic Disease
    PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant .
    PF-622
  • HY-10862

    Benzothiazole analog 3

    FAAH Autophagy Cancer
    FAAH inhibitor 1 (Benzothiazole analog 3) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 18±8 nM .
    FAAH inhibitor 1
  • HY-19740
    BIA 10-2474
    2 Publications Verification

    FAAH Autophagy Neurological Disease
    BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.
    BIA 10-2474
  • HY-N2365
    Macamide B
    2 Publications Verification

    N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1

    FAAH Autophagy Others
    Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).
    Macamide B
  • HY-111389

    FAAH Autophagy Metabolic Disease
    FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC50s of 145 nM and 650 nM for rat and human FAAH, respectively.
    FAAH-IN-1
  • HY-139384

    FAAH Neurological Disease
    FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC50 of 0.153 μM .
    FAAH inhibitor 2
  • HY-158784

    FAAH Others
    Arachidonoyl m-Nitroaniline (AmNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity. Arachidonoyl m-Nitroaniline is a FAAH substrate .
    Arachidonoyl m-nitroaniline
  • HY-161965

    FAAH Neurological Disease
    MK-3168 (12C) is a FAAH inhibitor with IC50 values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. 11C MK-3168 can be used as FAAH PET tracer .
    MK-3168 (12C)
  • HY-N3033
    N-​Benzyllinolenamide
    1 Publications Verification

    FAAH Autophagy Metabolic Disease
    N-​Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 41.8 μM .
    N-​Benzyllinolenamide
  • HY-15250
    JZL195
    4 Publications Verification

    FAAH MAGL Autophagy Neurological Disease
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
    JZL195
  • HY-111199

    FAAH Neurological Disease
    JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments .
    JP83
  • HY-120300

    Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
    UCM710
  • HY-79511
    FAAH-IN-2
    1 Publications Verification

    O-Desmorpholinopropyl Gefitinib

    FAAH Autophagy Others
    FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
    FAAH-IN-2
  • HY-123863

    FAAH Neurological Disease
    SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .
    SSR411298
  • HY-101457

    MAGL Metabolic Disease
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430
  • HY-125967

    FAAH Neurological Disease
    AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease .
    AM 374
  • HY-144738

    Epoxide Hydrolase FAAH Inflammation/Immunology
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .
    Dual FAAH/sEH-IN-1
  • HY-14595
    Biochanin A
    Maximum Cited Publications
    9 Publications Verification

    4-Methylgenistein; Olmelin

    FAAH Autophagy Endogenous Metabolite Neurological Disease Cancer
    Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
    Biochanin A
  • HY-120369

    FAAH Neurological Disease
    URB532 is an inhibitor for fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. URB532 increases levels of arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain, and exhibits anxiolytic and analgesic effects .
    URB532
  • HY-146341

    FAAH MAGL Neurological Disease
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH-IN-5
  • HY-18081

    FAAH Autophagy Metabolic Disease
    PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile .
    PF 750
  • HY-119283
    MAGL-IN-5
    1 Publications Verification

    CAY10499

    MAGL FAAH Metabolic Disease
    MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC50 values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively .
    MAGL-IN-5
  • HY-120957

    AMC-AA; 7-Amino-4-methyl coumarin-arachidonamide

    Endogenous Metabolite Metabolic Disease
    AMC arachidonoyl amide (AMC-AA) is one of several fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate anandamide.2 Exposure of AMC-AA to FAAH activity results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm. This allows the fast and convenient measurement of FAAH activity using a simple cuvette or microplate fluorometer.
    AMC Arachidonoyl Amide
  • HY-134110

    Endogenous Metabolite Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N-methyl amide is an analog of anandamide that binds to the human central cannabinoid (CB1) receptor with a Ki of 60 nM. It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    N-Methylarachidonamide
  • HY-134055

    Arachidonic acid-N,N-dimethyl amide

    Cannabinoid Receptor Metabolic Disease
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    Arachidonoyl-N,N-dimethyl amide
  • HY-118158

    FAAH Neurological Disease
    FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .
    FAAH/MAGL-IN-4
  • HY-14595R

    4-Methylgenistein(Standard); Olmelin (Standard)

    FAAH Autophagy Endogenous Metabolite Neurological Disease Cancer
    Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
    Biochanin A (Standard)
  • HY-120971

    DepNA

    Endogenous Metabolite Metabolic Disease
    N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.
    N-Decanoyl p-Nitroaniline
  • HY-146342

    FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-121422

    MAGL Histamine Receptor Inflammation/Immunology
    JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .
    JZP-361
  • HY-134019

    Others Others
    Arachidonoyl p-nitroaniline is a substrate for the hydrolysis of p-nitroaniline by FAAH in Dictyostelium discoideum with long-chain unsaturated fatty acids. Arachidonoyl p-nitroaniline can be used in enzyme kinetic studies. Examples include determining the hydrolysis rate of Arachidonoyl p-nitroaniline and analyzing the fatty acid amide hydrolase activity of recombinant His-FAAH purified from Dictyostelium to characterize the binding and catalytic specificity of mammalian FAAH enzymes .
    Arachidonoyl p-nitroaniline
  • HY-103461

    FAAH Neurological Disease
    FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .
    FAAH-IN-6
  • HY-116710

    FAAH Others
    3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone (compound 45) is a potential inhibitor of fatty acid amide hydrolase (FAAH) (pI50: 5.89) and is active against CB(1) and CB(2) ) Lack of affinity for cannabinoid receptors .
    3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
  • HY-103337

    Arachidonyl serotonin; AA-5-HT

    FAAH TRP Channel Neurological Disease
    N-Arachidonoylserotonin (Arachidonyl serotonin; AA-5-HT) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 value of 1~12 µM. N-Arachidonoylserotonin acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels (IC50=70~100 nM). N-Arachidonoylserotonin is analgesic in rodents .
    N-Arachidonoylserotonin
  • HY-10865
    LY2183240
    2 Publications Verification

    FAAH Autophagy Neurological Disease
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
    LY2183240
  • HY-N2512
    1-Monomyristin
    1 Publications Verification

    FAAH Bacterial Fungal Endogenous Metabolite Autophagy Infection
    1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans .
    1-Monomyristin
  • HY-B0182
    Carmofur
    3 Publications Verification

    HCFU

    Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase Infection Inflammation/Immunology Cancer
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
    Carmofur
  • HY-115004

    Others Neurological Disease
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites .
    MM-433593
  • HY-118210

    FAAH Metabolic Disease
    PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.
    PHOP
  • HY-B0182R

    Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase Infection Inflammation/Immunology Cancer
    Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .
    Carmofur (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: